LINC00922: A Potential Drug Target and Biomarker (G283867)

Target Name: LINC00922

NCBI ID: G283867

LINC00922

Other Name(s): Lnc-LALC | long intergenic non-protein coding RNA 922 | Long intergenic non-protein coding RNA 922

LINC00922: A Potential Drug Target and Biomarker

LINC00922 is a long non-coding RNA (lncRNA) that has been identified as a potential drug target and biomarker. It is located on chromosome 6p21.3 and has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion. LINC00922 has also been associated with various diseases, including cancer and neurodegenerative diseases.

The search for potential drug targets and biomarkers has become a major focus in the field of pharmacology in recent years. These targets are identified based on their ability to interact with specific drugs or to regulate cellular processes that are associated with the disease. LINC00922 is one of the most promising candidates for a drug target due to its unique biology and the potential impact it could have on various diseases.

Properties of LINC00922

LINC00922 is a 22-kDa RNA molecule that is located on chromosome 6p21.3. It is one of the long non-coding RNAs that have been identified as potential drug targets. LINC00922 is composed of 1,212 amino acid residues and has a calculated molecular mass of 19.9 kDa.

LINC00922 is expressed in various tissues and cells, including brain, pancreas, and various cancer types. It has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion. LINC00922 has also been associated with various diseases, including cancer and neurodegenerative diseases.

Drug Target Potential

LINC00922 is a potential drug target due to its unique biology and the potential impact it could have on various diseases. One of the main reasons for its potential as a drug target is its involvement in cell adhesion and migration. LINC00922 has been shown to be involved in the regulation of cell-cell adhesion and has been linked to the development of various diseases, including cancer.

Additionally, LINC00922 has been shown to be involved in the regulation of cell migration. It has been shown to be involved in the migration of various cell types, including neural cells, and has been linked to the development of various neurodegenerative diseases.

Another potential mechanism by which LINC00922 may be a drug target is its involvement in the regulation of cellular processes that are associated with the disease. LINC00922 has been shown to be involved in the regulation of various cellular processes, including cell signaling, DNA replication, and apoptosis.

Biomarker Potential

LINC00922 has also been identified as a potential biomarker for various diseases. Its involvement in various cellular processes and its association with various diseases make it an attractive candidate for use as a biomarker.

One of the main potential applications of LINC00922 as a biomarker is its ability to be used as a diagnostic marker for various diseases, including cancer. LINC00922 has been shown to be expressed in various types of cancer and has been used as a potential biomarker for cancer diagnosis and treatment.

Another potential application of LINC00922 as a biomarker is its ability to be used as a therapeutic target. By inhibiting the activity of LINC00922, it may be possible to treat various diseases, including cancer.

Conclusion

In conclusion, LINC00922 is a promising candidate for a drug target and biomarker. Its unique biology and the potential impact it could have on various diseases make it an attractive candidate for further investigation. Further studies are needed to fully understand the biology of LINC00922 and its potential as a drug

Protein Name: Long Intergenic Non-protein Coding RNA 922

The "LINC00922 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00922 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets